Drug Profile
KEL 01
Alternative Names: KEL-01Latest Information Update: 05 Sep 2023
Price :
$50
*
At a glance
- Originator Sirona Biochem
- Class Glycopeptides
- Mechanism of Action Collagen modulators; Gene expression modulators; NF-E2-related factor 2 modulators; Protein synthesis modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Acne vulgaris; Keloids
Highest Development Phases
- Discontinued Acne vulgaris; Keloids
Most Recent Events
- 05 Sep 2023 Discontinued - Preclinical for Keloids in Canada (unspecified route)
- 05 Sep 2023 Discontinued for Acne vulgaris in Canada (unspecified route)
- 28 Jun 2020 No recent reports of development identified for preclinical development in Keloids in Canada